

1624  
PATENT

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 01-019-A)

In the Application of:

Guiling Li, et al.

Serial No.: 10/038,069

Filed: December 21, 2001

For: Benzimidazole and Pyridylimidazole Derivatives



Examiner: Kahsay Habte

Art Unit: 1624

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Response to the Office Action Mailed October 7, 2004; and
  - b) Return Receipt Postcard.
2. With respect to fees:
  - a) No fee is due.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 7, 2005.

Respectfully submitted,

Dated: January 7, 2005

Raafat M. Shaltout  
Raafat M. Shaltout  
Registration No. 45,092

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

on JANUARY 7, 2005 (Date of Deposit).

(Date of Deposit).

Page 4 Date

29

Name

Name \_\_\_\_\_

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. 01-019-A)

RESPONSE TO THE OFFICE ACTION  
MAILED OCTOBER 7, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Office Action mailed October 7, 2004,  
Applicants respectfully request the Examiner to reconsider the  
above-identified patent application in view of the following  
amendments and remarks.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the claims are reflected in the Listing of  
Claims which begins on page 3 of this paper.

Remarks begin on page 44 of this paper.